Altimmune (ALT) CSO acquires 875 ESPP shares at $2.414
Rhea-AI Filing Summary
Altimmune, Inc. Chief Scientific Officer Roberts M Scot acquired 875 shares of common stock on July 31, 2026 through the company’s 2019 Employee Stock Purchase Plan. The shares were purchased at $2.414 per share, equal to 85% of that day’s closing price, bringing his direct holdings to 113,699 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 875 shares
Net Buy
1 txn
Insider
Roberts M Scot
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock, par value $0.0001 F1, F2 | 875 | $2.414 | $2K |
Holdings After Transaction:
Common Stock, par value $0.0001 — 113,699 shares (Direct)
Footnotes (2)
- F1. These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026.
- F2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026.
Key Figures
ESPP shares acquired: 875 shares
Purchase price: $2.414 per share
Holdings after transaction: 113,699 shares
+1 more
4 metrics
ESPP shares acquired
875 shares
Common stock purchased on July 31, 2026 under 2019 ESPP
Purchase price
$2.414 per share
ESPP purchase price equal to 85% of July 31, 2026 closing price
Holdings after transaction
113,699 shares
Direct common stock ownership following ESPP purchase
ESPP discount
85% of closing price
Shares purchased at 85% of Altimmune common stock closing price on July 31, 2026
Key Terms
Employee Stock Purchase Plan, ESPP, par value, closing price
4 terms
Employee Stock Purchase Plan financial
"participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
ESPP financial
"It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026"
An Employee Stock Purchase Plan (ESPP) is a company program that lets employees buy the company’s shares at a reduced price, usually by setting aside a small portion of their pay over time. It matters to investors because it encourages employees to own part of the business—like giving staff a discounted membership— which can boost commitment and performance, while also potentially increasing the number of shares available and affecting shareholder value.
par value financial
"Common Stock, par value $0.0001"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
closing price financial
"purchased based on 85% of the closing price of the Issuer's common stock"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Altimmune (ALT) report for Roberts M Scot?
Altimmune reported that Chief Scientific Officer Roberts M Scot acquired 875 common shares on July 31, 2026. The shares were purchased through the 2019 Employee Stock Purchase Plan at $2.414 per share, equal to 85% of that day’s closing price, raising his holdings to 113,699 shares.
Was the Altimmune (ALT) insider purchase made under an Employee Stock Purchase Plan?
Yes. The acquisition of 875 shares by Roberts M Scot was made through Altimmune’s 2019 Employee Stock Purchase Plan. It relates to the ESPP purchase period running from February 1, 2026 through July 31, 2026, with pricing set at 85% of the closing share price.
Did the Altimmune (ALT) Form 4 disclose any stock sales by Roberts M Scot?
No. The Form 4 reports only an acquisition of 875 Altimmune common shares via the ESPP. There are no disclosed stock sales, derivative exercises, or other dispositions by Roberts M Scot in this particular filing, and post-transaction holdings remain entirely direct.